Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: A single-dose hyperglycaemic clamp study

Diabetologia

Volumn 50, Issue 7, 2007, Pages 1384-1387

  Farret, A ^a,b   Chevassus, H ^a,b   Roux, B ^a,b   Petit, P ^c   Galtier, F ^d  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d HÔPITAL SAINT ELOI   (France)

Author keywords

C Peptide; Diabetes; Healthy volunteers; Hyperglycaemic clamp; Insulin clearance; Insulin secretion; Insulin sensitivity; Rosiglitazone; Thiazolidinediones

Indexed keywords

C PEPTIDE; INSULIN; PLACEBO; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; NORMAL HUMAN; PANCREAS ISLET BETA CELL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE;

ADULT; BODY MASS INDEX; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PILOT PROJECTS; PLACEBOS; THIAZOLIDINEDIONES; TIME FACTORS; VASODILATOR AGENTS;

EID: 34249939988     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0682-4     Document Type: Article

References (8)

1. Lehman JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956
2. Kim SH, Abbasi F, Chu JW et al (2005) Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 54:2447-2452
3. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176
4. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
5. Polonsky KS, Given BD, Hirsch L et al (1988) Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 81:435-441
6. Mitrakou A, Vuorinen-Markkola H, Raptis G et al (1992) Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemia clamp. J Clin Endocrinol Metab 75:379-382
7. Polonsky KS, Licinio-Paixao J, Given BD et al (1986) Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 77:98-105
8. Brunmair B, Gras F, Neschen S et al (2001) Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression. Diabetes 50:2309-2315